Tosoh

How Tosoh Biosciences is contributing to a fascinating project on a mission to develop a continuous production process using Escherichia Coli

How can multi-column chromatography support companies as they set their sights on intensified bioprocesses?

Since the beginning of the pandemic, the public has realized how essential the biotechnology industry is in securing our civilization's future.

Oligonucleotide-based therapeutics present manufacturers with specific processing and characterization challenges.

Explore TOSOH’s expertise across all stages of therapeutic antibody development.

Why salt-tolerant resins make for “happier” biomolecules with better binding.

Innovation is being boosted in manufacturing and purification techniques.

Using the right chromatography resin can make all the difference to antibody fragment manufacture

Oligonucleotide-based therapeutics have been investigated over the last decades and their promise as a new drug modality is now being realized.

Discover the better performance of Ca++Pure-HA

We developed a capturing method for antibody fragments that allows reducing the costs of the step by almost 80%.

The use of synthetic oligonucleotide therapeutics continues to grow because of their effectiveness in the treatment of devastating diseases.

Biotherapeutics are generally larger molecules such as peptides, proteins and monoclonal antibodies

In many stages of mAb development, cell culture samples must be screened for IgG titer.

Downstream processing is responsible for up to 80 percent of the entire production costs of biotherapeutics.

The first antisense drugs were approved, and clinical trials using siRNA show promising developments.

Discover over twenty application notes on biopharmaceutical purification.

Antibody-drug conjugates (ADCs) are promising anticancer biopharmaceuticals with one of the highest annual growth rates.